Yajima Shin, Miyagawa Shigeru, Fukushima Satsuki, Sakai Yoshiki, Iseoka Hiroko, Harada Akima, Isohashi Kayako, Horitsugi Genki, Mori Yuki, Shiozaki Motoko, Ohkawara Hirotatsu, Sakaniwa Ryoto, Hatazawa Jun, Yoshioka Yoshichika, Sawa Yoshiki
Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Osaka, Japan.
JACC Basic Transl Sci. 2019 May 8;4(3):318-331. doi: 10.1016/j.jacbts.2018.12.006. eCollection 2019 Jun.
Intravenously injected ONO-1301-containing nanoparticles (ONO-1301NPs), unlike an ONO-1301 solution, selectively accumulated in the ischemia/reperfusion (I/R)-injured myocardium of rats and contributed to the prolonged retention of ONO-1301 in the targeted myocardial tissue. In the ischemic area, proangiogenic cytokines were up-regulated and inflammatory cytokines were down-regulated upon ONO-1301NP administration. Consequently, ONO-1301NP-injected rats exhibited a smaller infarct size, better-preserved capillary networks, and a better-preserved myocardial blood flow at 24 h after I/R injury, compared with those in vehicle-injected or ONO-1301 solution-injected rats. ONO-1301NPs attenuate the myocardial I/R injury via proangiogenic and anti-inflammatory effects of the drug.
与ONO - 1301溶液不同,静脉注射含ONO - 1301的纳米颗粒(ONO - 1301NPs)可选择性地积聚在大鼠缺血/再灌注(I/R)损伤的心肌中,并有助于ONO - 1301在靶向心肌组织中长时间保留。在缺血区域,给予ONO - 1301NPs后促血管生成细胞因子上调,炎症细胞因子下调。因此,与注射赋形剂或ONO - 1301溶液的大鼠相比,注射ONO - 1301NPs的大鼠在I/R损伤后24小时梗死面积更小,毛细血管网络保存更好,心肌血流保存更好。ONO - 1301NPs通过药物的促血管生成和抗炎作用减轻心肌I/R损伤。